{"id":"experimental-ezetimibe-rosuvastatin-telmisartan","safety":{"commonSideEffects":[{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Hyperkalemia"}]},"_chembl":{"chemblId":"CHEMBL1017","moleculeType":"Small molecule","molecularWeight":"514.63"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ezetimibe selectively inhibits cholesterol absorption in the small intestine, while rosuvastatin inhibits HMG-CoA reductase to reduce hepatic cholesterol synthesis. Telmisartan is an angiotensin II receptor blocker that reduces blood pressure and provides cardiovascular protection. Together, these three agents address multiple cardiovascular risk factors—dyslipidemia and hypertension—in a single formulation.","oneSentence":"This combination reduces cholesterol and blood pressure by inhibiting intestinal cholesterol absorption and HMG-CoA reductase while blocking angiotensin II receptors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:11:56.076Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia and hypertension in patients requiring combination therapy"},{"name":"Cardiovascular risk reduction in dyslipidemic hypertensive patients"}]},"trialDetails":[{"nctId":"NCT04659070","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of Co-administrated Ezetimibe/Rosuvastatin and Telmisartan in Patients With Essential Hypertension and Primary Hypercholesterolemia","status":"UNKNOWN","sponsor":"Hanlim Pharm. Co., Ltd.","startDate":"2020-07-15","conditions":"Primary Hypercholesterolemia, Hypertension","enrollment":156}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Experimental : Ezetimibe / Rosuvastatin + Telmisartan","genericName":"Experimental : Ezetimibe / Rosuvastatin + Telmisartan","companyName":"Hanlim Pharm. Co., Ltd.","companyId":"hanlim-pharm-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination reduces cholesterol and blood pressure by inhibiting intestinal cholesterol absorption and HMG-CoA reductase while blocking angiotensin II receptors. Used for Hypercholesterolemia and hypertension in patients requiring combination therapy, Cardiovascular risk reduction in dyslipidemic hypertensive patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}